Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Antagonist activity at human RARB in an in vitro cell-based assay measured by time-resolved fluorescence resonance energy transfer method
Assay data:3 Active, 36 Tested
SummaryRelated BioAssays by Target
Agonist activity at human RARB in an in vitro cell-based assay measured by time-resolved fluorescence resonance energy transfer method
Assay data:1 Active, 38 Tested
Agonist activity at human RAR-beta expressed in CHO-K1 cells by PathHunter assay
Assay data:1 Active, 1 Activity ≤ 1 nM, 1 Activity ≤ 1 µM, 1 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Agonist activity at human RAR-beta expressed in CHO-K1 cells assessed as maximum relative efficacy at 100 uM by PathHunter assay relative to 9-cis-retinoic acid
Assay data:1 Tested
SummaryPubMed CitationRelated BioAssays by Target
Agonist activity at human RAR-beta2 receptor
Assay data:2 Active, 2 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Agonist activity at human RARbeta (177 to 455 residues) in Cos7 cells transfected with LBD-Gal4 and pGL435 Gal4 UAS Luc reporter plasmid at 10 uM by reporter gene assay
Transactivation assays from US Patent US10752616: "Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists"
Assay data:46 Active, 2 Activity ≤ 1 nM, 46 Activity ≤ 1 µM, 46 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
Retinoid Competition Binding Assay from Article 10.1006/jmbi.2000.4032: "Structural basis for isotype selectivity of the human retinoic acid nuclear receptor."
Assay data:9 Active, 3 Activity ≤ 1 nM, 9 Activity ≤ 1 µM, 9 Tested
Retinoid Nuclear Receptor Activity from US Patent US10188615: "Alkoxy compounds for disease treatment"
Assay data:2 Active, 1 Activity ≤ 1 nM, 2 Activity ≤ 1 µM, 2 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Target
Agonist activity RARbeta (unknown origin) assessed as induction of receptor transactivation
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
Transactivation of GAL4 DBD-fused human RARbeta-LBD expressed in HEK293 cells by beta-lactamase reporter gene based assay
Antagonist activity at RAR (unknown origin) by Alpha Screen assay
Agonist activity at RAR (unknown origin) by Alpha Screen assay
Assay data:1 Active, 1 Activity ≤ 1 nM, 1 Activity ≤ 1 µM, 2 Tested
Agonist activity at RAR (unknown origin) at 10 uM
Agonist activity at human Gal4-DBD fused RARbeta LBD expressed in HEK293T cells at 30 uM after 12 to 14 hrs by luciferase reporter gene assay
Assay data:1 Active, 1 Tested
Agonist activity at Gal4-LBD fused RARbeta (unknown origin) expressed in HEK293T cells at 20 uM after 14 to 16 hrs by dual-Glo luciferase assay
Agonist activity at Gal4-LBD fused RARbeta (unknown origin) expressed in HEK293T cells at 10 uM after 14 to 16 hrs by dual-Glo luciferase assay
Agonist activity at RAR beta (unknown origin)
Assay data:2 Tested
RNAi screen for vemurafenib enhancer genes in BRAFV600 melanoma - Primary Screen
Assay data:790 Active, 18119 Tested
Summary
Agonist activity at recombinant GST-tagged human RARbeta LBD assessed as fluorescein-labeled coactivator peptide recruitment preincubated with enzyme followed by coactivator addition by LanthaScreen TR-FRET assay
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on